predictors and outcomes of extramedullary disease in multiple myeloma
Published 4 hours ago • 4 plays • Length 1:25Download video MP4
Download video MP3
Similar videos
-
1:50
outcomes of patients with dlbcl following asct and/or car-t
-
1:33
outcomes of hodgkin lymphoma patients who receive a second asct
-
1:00
the role of non-covalent btk inhibitors in the treatment of non-hodgkin lymphoma
-
2:55
the discovery of pathogenic germline variants in patients with myeloma
-
1:48
the importance of evaluating qualitative outcomes of patients with cll on targeted therapy
-
3:06
what happens in treatment failure in aml?
-
2:05
donor lymphocyte infusion for relapsed myelofibrosis in the post-allosct setting
-
9:50
[icml 2023] change is hard: a closer look at subpopulation shift
-
1:37
a prospective trial of radiation-free chemotherapy in high- and low-risk hl
-
8:57
outcomes of sct in t-all and t-lbl
-
3:10
is there a benefit to rituximab maintenance after first-line bendamustine-rituximab for mcl?
-
1:05
using machine learning to predict the outcomes of patients with ndmm being treated with vrd
-
5:46
the use of allogeneic transplantation in the era of checkpoint blockade therapy in hodgkin lymphoma
-
3:36
outcomes of patients with newly diagnosed crlf2-rearranged b-all
-
3:17
pet imaging to predict treatment outcomes: follow-up from the echelon-2 trial
-
0:50
update on the pimms trial of ivosidenib for patients with idh1-mutated ccus
-
1:04
long-term survival outcomes in pts with mf treated with momelotinib vs danazol in the momentum trial
-
1:20
improving patient outcomes in ctcl: clinical collaboration and novel agents
-
3:09
treatment strategies for chl patients after auto-hsct
-
1:53
canova trial: vendex versus pomdex in patients with r/r multiple myeloma
-
1:09
outcomes following haploidentical & cord blood transplantation in pediatric patients with aml